Bacterial microbiome used as marker for gastric cancer diagnosis and application of bacterial microbiome
By analyzing the differences in microbial composition of gastric tissue samples of gastric cancer patients and healthy individuals, bacterial microbiome markers were determined, which solved the problem of early diagnosis of gastric cancer in the prior art, achieved accurate screening and diagnosis of gastric cancer, and improved the accuracy of detection .
Patent Information
- Application Number
- CN202410780394.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-18
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to effectively diagnose and identify symbiotic and pathogenic bacteria related to gastric cancer, especially the participation of non-Herrelic pylori microorganisms in gastric cancer, which has not been fully explored, making it difficult to detect gastric cancer early.
Through differential analysis of the microbial composition of gastric tissue samples of gastric cancer patients and healthy individuals, bacterial microbiome markers, such as Candidatus_Odyssella, Gemella, Veillonella, etc., were used to non-invasive early diagnosis of gastric cancer, methods including DNA extraction, 16S rRNA gene sequencing and Abundance comparison.
Accurate and reliable screening and diagnosis of early gastric cancer is achieved. By detecting the abundance of Streptococcus mitis, the possible existence of gastric cancer is accurately judged, and the accuracy and reliability of the diagnosis are improved.
Smart Images

Figure CN119020511A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomarkers, and in particular to a bacterial microbiome as a marker for gastric cancer diagnosis and application thereof. Background Art
[0002] Gastric cancer (GC) is on the rise worldwide. It ranks fifth in the number of new cases and fourth in causing death. The development of GC usually goes through a multi-step process from atrophic gastritis (AG) to intestinal metaplasia (IM) and finally to GC. Although the etiology and pathogenesis of gastric cancer are still unclear, it has been shown that exposure to environmental carcinogens (such as toxic chemicals and Helicobacter pylori) increases the risk of cancer, and the microbiota can also respond to changing environmental conditions by changing its own composition and gene expression. The stomach has always been considered a "hostile place" for bacteria because the highly acidic gastric juice is not suitable for microbial growth.
[0003] In recent years, people have begun to pay attention to the role of microorganisms in tumors. Microorganisms may affect tumor progression by regulating tumor biology, immune-inflammatory responses, and therapeutic efficiency. Traditionally, commensal and pathogenic interactions have been considered different manifestations of bacteria-host interactions. Helicobacter pylori (HP) has been widely recognized as an important player in the process of gastric cancer. However, only about 1% to 2% of HP-positive patients will develop gastric cancer. In addition, it should be emphasized that a considerable proportion of gastric cancer patients always have negative HP test results, which also means that non-HP microorganisms are involved in the occurrence of gastric cancer. Therefore, it is of great significance to identify and analyze commensal bacteria and pathogenic bacteria associated with gastric cancer.
[0004] The advancement of high-throughput sequencing technology has provided a strong technical guarantee for exploring the differences in microbial composition and abundance in the stomach between healthy people and gastric cancer patients. Studies have shown that compared with precancerous lesions, the gastric mucosal microbiota of gastric cancer patients is significantly dysregulated, characterized by the enrichment of certain pathogenic bacterial genera. This dysbiosis may be significantly related to maintaining persistent pain in the gastric mucosa, thereby promoting the development of gastric cancer. Some studies have shown that the proportion of lactic acid bacteria in the microbial flora of gastric cancer patients is higher, which may aggravate the inflammatory response and promote tumor cell proliferation. Fusobacterium is reported to be an anaerobic bacterium widely distributed in the oral cavity that regulates epithelial-mesenchymal transition, thereby promoting the spread and invasion of gastric cancer cells. However, compared with the widely studied intestinal microorganisms, the interaction between the microbial community in the tumor and the occurrence of gastric cancer remains a mystery and needs further exploration. Summary of the invention
[0005] 1. Technical problems to be solved: In response to the above technical problems, the present invention provides an intratumoral bacterial microbiome as a marker for gastric cancer diagnosis and its application.
[0006] 2. Technical solution: A bacterial microbiome marker for gastric cancer diagnosis, wherein the bacterial microbiome is selected at the genus level or above in bacteria, and the marker is: Candidatus_Odyssella , Gemella, Veillonella , Ferritrophicum , Prevotella , Lentimicrobium , Woodsholea , Streptococcus , Hyphomicrobium , Terrimonas , Allobaculum , Sulfurimonas , Georgfuchsia , Fusobacterium , Thiobacillus , Simplicispira , Hydrogenophaga , Rubrobacter , Aquimonas One or more of .
[0007] The bacterial microbiome markers for gastric cancer diagnosis provided by the present invention are determined by the inventors through comparative analysis and verification of the differences in the abundance of microorganisms in gastric tissue samples of a large number of gastric cancer patients and a large number of healthy control individuals. Using bacterial microbial markers, it is possible to determine the probability of an individual suffering from gastric cancer or being in a healthy state, and can be used for non-invasive early detection or auxiliary detection of gastric cancer.
[0008] How to confirm the individual's status by the following method, which is used for non-disease diagnosis purposes, the method comprising: (1) Extracting total DNA from the gastric tissue of the individual to be identified; (2) PCR amplification of the 16S rRNA gene from the V3-V4 region and cleaning of the PCR amplification product; (3) Prepare the sequencing library and sequence it after indexing and assessing the library integrity; (4) Taxonomic annotation of the sequencing results to determine the abundance of various bacterial microbiomes in the markers; (5) comparing the abundance of various bacterial microbiomes in the marker with their abundance in the control group, and determining the status of the individual based on the comparison results obtained; The control group includes gastric tissue samples from individuals with gastric cancer and healthy individuals without gastric cancer.
[0009] Preferably, the DNA is extracted in step (1) using the EZNA® soil DNA extraction commercial kit.
[0010] Preferably, the PCR amplification in step (2) uses primers 338F (ACTCCTACGGGAGGCAGCAG) and 806R (GGACTACHVGGGTWTCTAAT); the PCR protocol starts with an initial denaturation at 95°C for 3 minutes, followed by denaturation at 95°C for 30 seconds, annealing at 53°C for 30 seconds, and extension at 72°C for 10 minutes.
[0011] Preferably, the PCR amplification product is cleaned in step (2) using a Qiagen gel extraction kit.
[0012] Preferably, the step (3) is used to prepare the sequencing library using the TruSeq® DNA PCR-Free Sample Preparation Kit, the library integrity is assessed using a Qubit@2.0 fluorometer and an Agilent Bioanalyzer 2100 system, and the library is sequenced on an Illumina Miseq system.
[0013] Specifically, the taxonomic annotation process is as follows: (1) Delete mismatches, deletions, and duplications, and only allow 2 nucleotide mismatches; (2) Using UPARSE.7, taxonomic units (OTUs) with a similarity of more than 97% were clustered into the same OTU; (3) The abundance of various bacterial microbiomes in the detection markers.
[0014] In addition, the present invention provides a kit for detecting the bacterial microbiome markers described in claim 1.
[0015] 3. Beneficial effects: This paper describes the role of bacteria in the gastric microenvironment in the occurrence and development of gastric cancer (GC), and finds that the bacterial content of a bacterial microbiome in GC tissue can be used as an effective detection marker for GC. This marker can be used to accurately and reliably screen and diagnose GC. For example, by detecting the bacterial content in the tissue of GC patients, Streptococcus mitis The level can accurately determine whether there is a possibility of cancer or GC. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 :The possible mechanism of action of the microenvironment of gastric cancer flora in GC group; Figure 2 : Alpha diversity of microbiota between GC and HC groups (measured by chao1, Shannon, observed_species) (p<0.001, p<0.001, p<0.05 ( Figure 2A), β diversity (calculated by PCA (Principal Component Analysis) and NMDS (Non-Metric Multidimensional Scaling)) ( Figure 2 B) Venn diagram and bar chart of OUT among the three groups ( Figure 2 C) Bacteria distribution classification analysis diagram ( Figure 2 D) Branch diagram ( Figure 2 E) and linear discriminant analysis effect size plot (LEfSe) ( Figure 2 F); Figure 3 :Analysis of the abundance of Streptococcus g__Streptococcus in three groups of gastric cancer patients, adjacent patients and normal patients ( Figure 3 A), FISH verification ( Figure 3 B); Streptococcus mitis ROC curve analysis ( Figure 3 C) and mass spectrometry identification ( Figure 3 D); In vivo imaging of tumor-bearing mice ( Figure 3 E) Body weight and survival curve of tumor-bearing mice ( Figure 3 F) and HE and immunohistochemical staining of tissues ( Figure 3 G); Figure 4 :A random forest analysis was performed on the differential bacteria in normal tissues of gastric cancer patients, and the top 20 differential bacteria were screened out ( Figure 4 A), and a diagnostic model was established based on these differential bacteria ( Figure 4 B). DETAILED DESCRIPTION
[0017] The present invention will be described in detail below with reference to the accompanying drawings.
[0018] Embodiment 1: 1.1 Collection of tissue samples and DNA extraction Patients clinically diagnosed with gastric cancer were selected, and their surgically removed gastric cancer tissues (GC, 23 cases) were collected. At the same time, their paracancerous gastric cancer tissues (PC, 23 cases) were collected, immediately washed three times with sterile saline, added with 1 mL of tissue preservation solution, and stored in a -80 ℃ refrigerator. At the same time, healthy gastric tissues scraped from healthy people during gastroscopy (HC, 11 cases) were collected, washed and treated with tissue preservation solution, and stored in a -80 ℃ refrigerator. The total DNA in the three groups of tissues was extracted using the EZNA® soil DNA extraction commercial kit and stored in a -80 ℃ refrigerator for future use. The possible action principle of the gastric cancer microenvironment in the GC group is shown in the figure below. Figure 1 shown.
[0019] 1.2 16S sequencing of bacteria in tissues The 16S rRNA gene from the V3-V4 region was amplified using primers 338F (ACTCCTACGGGAGGCAGCAG) and 806R (GGACTACHVGGGTWTCTAAT). The PCR protocol started with an initial denaturation at 95°C for 3 min, followed by denaturation at 95°C for 30 s, annealing at 53°C for 30 s, and extension at 72°C for 10 min. The PCR amplification was then cleaned using the Qiagen Gel Extraction Kit. Following this, sequencing libraries were prepared and indexed using the TruSeq® DNA PCR-Free SamplePreparation Kit following the instructions provided by the manufacturer. The integrity of the library was assessed using the Qubit@2.0 Fluorometer and the Agilent Bioanalyzer 2100 system. In the final step, the library was sequenced on the Illumina Miseq system, generating paired-end reads of 300 base pairs. The raw sequencing results were deposited in the Sequence Read Archive (SRA) database of the National Center for Biotechnology Information (NCBI) (accession code: PRJNA1093016).
[0020] 1.3 Taxonomic annotation of sequencing results The original 16S rRNA sequencing data were operated as follows: on a 50 bp moving window, 300 bp reads with an average quality score less than 20 were truncated, truncated reads less than 50 bp were discarded, and characters with ambiguous reads were discarded; based on overlapping sequences, only overlapping sequences of more than 10 bp were assembled. The maximum mismatch ratio in the overlapping region was 0.2. Reads that could not be assembled were discarded; samples were distinguished based on barcodes and primers, sequence directions were adjusted, barcodes were accurately matched, and only 2 nucleotide mismatches were allowed when matching primers. Operational taxonomic units (OTUs) with a similarity of 97% were clustered into the same OTU using UPARSE 7.1, and chimeric sequences were identified and removed.
[0021] Based on sequencing accuracy, alpha diversity was calculated using QIIME ( Figure 2 A), including observed_species, Shannon, chao1 and PD_whole_tree (p<0.001, p<0.001, p<0.05; sample points are colored according to disease phenotype and inter-group differences, β diversity analysis ( Figure 2 B) Bray-Curtis distance was calculated using principal component analysis (PCA) and NMDS (non-metric multidimensional scaling).
[0022] like Figure 2As shown in A and 2B, the HC group was significantly higher than the GC group at the four levels of observed_species index, chao1, Shannon, and PD_whole_tree, indicating that the alpha diversity of bacteria in the HC was higher than that in the GC group, indicating that the species abundance of bacteria in the HC group was higher. The results of PCA and NMDS analysis showed that the bacteria in the HC and GC groups were clearly divided into two groups, indicating that the composition of bacteria in the same type of tissue was highly unified. Both analyses showed that the operational taxonomic units (OTUs) of the three groups of patients were significantly clustered, indicating that the composition of the microbiota of GC patients was significantly different from that of other groups.
[0023] 1.4 Screening and diagnostic efficacy of differentially expressed bacteria in the GC group and their possible functional studies The differences in OUTs among the three groups were analyzed using Venn distribution, as Figure 2 As shown in C, there are 494 OUTs shared by the three groups, and HC, GC and Para-GC have 2296, 948 and 732 OUTs unique to them, respectively. The identified bacterial OTUs were classified and annotated according to the UNITE database ( Figure 2 D). And through the branch diagram ( Figure 2 E) and linear discriminant ( Figure 2 F) Analysis of effect size (LEfSe). The main genera in GC tissue included Streptococcus, Fusobacterium, Helicobacter, and Lactobacillus, and Thiobacillus, Desulfocapsa, and Ferritrophicum Enriched in the HC group ( Figure 2 D). In addition, the cladogram ( Figure 2 E) and linear discriminant ( Figure 2 F) The effect size analysis (LEfSe) showed that the relative enrichment of bacterial communities at the genus level was significantly different among the groups (LEfSe: p < 0.05, q < 0.05, LDA > 4.5).
[0024] Embodiment 2: 2.1 The abundance of Streptococcus in three groups of gastric cancer, adjacent tissues and normal patients was analyzed and it was found that the abundance of Streptococcus was very high in gastric cancer tissues ( Figure 3 A and confirmed its localization in the tumor by FISH ( Figure 3 B).
[0025] 2.2 ROC curve analysis was performed on bacteria isolated from tissues ( Figure 3 C) and mass spectrometry identification ( Figure 3 D) The bacteria were identified Streptococcus mitis .
[0026] 2.3 In vivo imaging of tumor-bearing mice ( Figure 3 E) and the weight and survival curve of tumor-bearing mice ( Figure 3 F) and HE and immunohistochemical staining of tissues ( Figure 3 G).
[0027] right Streptococcus mitis We performed ROC curve analysis and found that the area under the ROC curve was 1. Finally, we performed an animal bacterial flora gavage experiment on tumor-bearing mice and found that the tumor volume of gastric cancer mice was significantly reduced, and the survival time of mice after gavage was prolonged, confirming that it may be involved in the pathogenesis of gastric cancer.
[0028] Embodiment 3: The Random Forest package in R language was used for random forest modeling. The process was as follows: First, the data set was randomly divided into a training set (70%) and a test set (30%). All genera were modeled as a whole using the Random Forest package, and OBB (accuracy = 1-OOB) and MeanDecreaseAccuracy and MeanDecreaseGini importance ranking were obtained to screen out the top 20 differential bacteria, namely g__Candidatus_Odyssella , g__Gemella , g__Veillonella , g__ Ferritrophicum , g__Prevotella , g_Lentimicrobium , g__Woodsholea , g__ Streptococcus , g__Hyphomicrobium , g__Terrimonas , g__Allobaculum , g__Sulfurimonas , g__Georgfuchsia , g_Fusobacterium , g__Thiobacillus , g__Simplicispira , g__ Hydrogenophaga , g__Rubrobacter , g_Aquimonas , and a diagnostic model was established based on these differential bacteria ( Figure 4 A, 4B). The error rate (CV Error) was calculated using the 10-fold 5-fold cross-validation method, and the optimal number and type of modeling were obtained. Then the model was constructed using the optimal modeling combination, and the final model was confirmed. The model results were calculated using the training set, test set, and all samples, and the pROC package was used to calculate the AUC value and draw the ROC curve.
[0029] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
[0030] Although the present invention has been disclosed as above in terms of preferred embodiments, they are not intended to limit the present invention. Anyone skilled in the art can make various changes or modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the scope of protection defined by the claims of this application.
Claims
1. A bacterial microbiome marker for gastric cancer diagnosis, characterized in that: The bacterial microbiome is selected from bacteria at the genus level or above, and the markers are: Candidatus_Odyssella, Gemella, Veillonella, Ferritrophicum, Prevotella, Lentimicrobium, Woodsholea, Streptococcus, Hyphomicrobium, Terrimonas, Allobaculum, Sulfurimonas, Georgfuchsia, Fusobacterium, Thiobacillus, Simplicispira, Hydrogenophaga, Rubrobacter, Aquimonas One or more.
2. A method for determining an individual's status using the bacterial microbiome of claim 1 as a marker, the method being used for non-disease diagnosis purposes, characterized in that: The method comprises: (1) Extracting total DNA from the gastric tissue of the individual to be identified; (2) PCR amplification of the 16S rRNA gene from the V3-V4 region and cleaning of the PCR amplification product; (3) Prepare the sequencing library and sequence it after indexing and assessing the library integrity; (4) Taxonomic annotation of the sequencing results to determine the abundance of various bacterial microbiomes in the markers; (5) comparing the abundance of various bacterial microbiomes in the marker with their abundance in the control group, and determining the status of the individual based on the comparison results obtained; The control group includes gastric tissue samples from individuals with gastric cancer and healthy individuals without gastric cancer.
3. The method according to claim 2, characterized in that In step (1), DNA is extracted using the EZNA®soil DNA extraction commercial kit.
4. The method according to claim 2, characterized in that: The PCR amplification in step (2) used primers 338F (ACTCCTACGGGAGGCAGCAG) and 806R (GGACTACHVGGGTWTCTAAT); the PCR protocol started with an initial denaturation at 95°C for 3 minutes, followed by denaturation at 95°C for 30 seconds, annealing at 53°C for 30 seconds, and extension at 72°C for 10 minutes.
5. The method according to claim 2, characterized in that: In step (2), the PCR amplification product is cleaned using a Qiagen gel extraction kit.
6. The method according to claim 2, characterized in that In step (3), the sequencing library was prepared using the TruSeq® DNA PCR-Free Sample Preparation Kit, the library integrity was assessed using the Qubit@2.0 Fluorometer and Agilent Bioanalyzer 2100 system, and the library was sequenced on the Illumina Miseq system.
7. The method according to claim 2, characterized in that The taxonomic annotation process is: (1) Delete mismatches, deletions, and duplications, and only allow 2 nucleotide mismatches; (2) Using UPARSE.7, taxonomic units (OTUs) with a similarity of more than 97% were clustered into the same OTU; (3) The abundance of various bacterial microbiomes in the detection markers.
8. A kit for detecting the bacterial microbiome markers of claim 1.
